The Journal of Clinical Pharmacology

Cover image for The Journal of Clinical Pharmacology

Special Issue: The Emerging Scientific Discipline of Pharmacometrics

September 2010

Volume 50, Issue S9

Pages 6S–158S

  1. Editorial Preface

    1. Top of page
    2. Editorial Preface
    3. Integration
    4. Innovation
    5. Impact
    6. Editorial Commentary
    1. The Emerging Scientific Discipline of Pharmacometrics (page 6S)

      Marc Pfister and David Z. D'Argenio

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010377789

  2. Integration

    1. Top of page
    2. Editorial Preface
    3. Integration
    4. Innovation
    5. Impact
    6. Editorial Commentary
    1. ACoP: The Tools, Carpenters, and Architects Building the Discipline of Pharmacometrics (pages 7S–8S)

      Dr Richard C. Brundage, Dr Marc Pfister, Dr David Z. D'Argenio, Dr Marc R. Gastonguay, Dr Raymond Miller and Dr Stacey J. Tannenbaum

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376967

    2. Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success (pages 9S–19S)

      Dr Klaus Romero, Dr Brian Corrigan, Dr Christoffer W. Tornoe, Dr Jogarao V. Gobburu, Dr Meindert Danhof, Dr William R. Gillespie, Dr Marc R. Gastonguay, Dr Bernd Meibohm and Dr Hartmut Derendorf

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010377788

    3. Model-Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry (pages 20S–30S)

      Dr Julie A. Stone, Dr Christopher Banfield, Dr Marc Pfister, Dr Stacey Tannenbaum, Dr Sandy Allerheiligen, Dr Jeffrey D. Wetherington, Dr Rajesh Krishna and Dr Dennis M. Grasela

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010377628

    4. Model-Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development (pages 31S–46S)

      Dr Jeffrey D. Wetherington, Dr Marc Pfister, Dr Christopher Banfield, Dr Julie A. Stone, Dr Rajesh Krishna, Sandy Allerheiligen and Dr Dennis M. Grasela

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010377629

    5. Antiviral Information Management System (AIMS): A Prototype for Operational Innovation in Drug Development (pages 50S–55S)

      Pravin R. Jadhav, Lauren Neal, Jeff Florian, Ying Chen, Lisa Naeger, Sarah Robertson, Guoxing Soon and Debra Birnkrant

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376771

  3. Innovation

    1. Top of page
    2. Editorial Preface
    3. Integration
    4. Innovation
    5. Impact
    6. Editorial Commentary
    1. Bridging Pharmacology and Pathophysiology via Systems Modeling (pages 56S–57S)

      David Z. D'Argenio and Donald E. Mager

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010377505

    2. Models for Event-Driven Data: Longitudinal Daily Adverse Event and Dropout (pages 58S–62S)

      Raymond Miller, Kaori Ito and Bojan Lalovic

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376975

    3. Missing Data in Model-Based Pharmacometric Applications: Points to Consider (pages 63S–74S)

      Dr Marc R. Gastonguay, Dr Jonathan L. French, Dr Daniel F. Heitjan, Dr James A. Rogers, Dr Jae Eun Ahn and Dr Patanjali Ravva

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010378409

    4. Population Modeling of Filgrastim PK-PD in Healthy Adults Following Intravenous and Subcutaneous Administrations (pages 101S–112S)

      Dr Wojciech Krzyzanski, Dr Pawel Wiczling, Dr Phil Lowe, Dr Etienne Pigeolet, Dr Martin Fink, Dr Alexander Berghout and Dr Sigrid Balser

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376966

  4. Impact

    1. Top of page
    2. Editorial Preface
    3. Integration
    4. Innovation
    5. Impact
    6. Editorial Commentary
    1. Visualization Concepts to Enhance Quantitative Decision Making in Drug Development (pages 130S–139S)

      Dr Kevin Dykstra, Dr Richard Pugh and Dr Andreas Krause

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376969

    2. Fostering Culture and Optimizing Organizational Structure for Implementing Model-Based Drug Development (pages 146S–150S)

      Dr Liping Zhang, Dr Sandra R. Allerheiligen, Dr Richard L. Lalonde, Dr Donald R. Stanski and Dr Marc Pfister

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376976

    3. Pharmacometrics 2020 (pages 151S–157S)

      Jogarao V. S. Gobburu

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010376977

  5. Editorial Commentary

    1. Top of page
    2. Editorial Preface
    3. Integration
    4. Innovation
    5. Impact
    6. Editorial Commentary
    1. Defining the Future of Pharmacometrics: The American Society of Pharmacometrics (page 158S)

      Marc Pfister, Richard C. Brundage, Marc R. Gastonguay, Raymond Miller, Stacey J. Tannenbaum and David Z. D'Argenio

      Version of Record online: 7 MAR 2013 | DOI: 10.1177/0091270010377632

SEARCH

SEARCH BY CITATION